Literature DB >> 22182436

Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo.

A S Karadag1, E Tutal, D T Ertugrul, K O Akin, S G Bilgili.   

Abstract

Few studies have investigated the role of vitamin B12 metabolism in vitiligo. We tested the hypothesis that vitamin B12 and folate metabolism might have an influence on the pathogenesis of vitiligo. Full blood count and levels of folic acid, vitamin B12, homocysteine and holotranscobalamine were examined for 69 patients with vitiligo and 52 controls. The vitiligo group had higher levels of homocysteine (P < 0.01) and haemoglobin (P < 0.01) levels, and lower levels of vitamin B12 (P < 0.01) and holotranscobalamine (P < 0.0001) than the control group. Folic acid levels were similar for both groups. In a risk analysis, hyperhomocysteinaemia (≥ 15 μmol/L, P < 0.01) and vitamin B12 deficiency (< 200 pg/mL, P < 0.01) were significant risk factors for vitiligo. Patients with holotranscobalamine levels in the lowest quartile had an increased risk for co-occurrence of vitiligo (P < 0.005). Vitamin B12 deficiency and hyperhomocysteinaemia may share a common genetic background with vitiligo. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22182436     DOI: 10.1111/j.1365-2230.2011.04142.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

1.  Serum Homocysteine and Total Antioxidant Status in Vitiligo: A Case Control Study in Indian Population.

Authors:  Shikha Gupta; Paschal D'souza; Tapan Kumar Dhali; Sarika Arora
Journal:  Indian J Dermatol       Date:  2016 Mar-Apr       Impact factor: 1.494

2.  Correlation between Serum Homocysteine and Vitiligo Area Scoring Index.

Authors:  Dina R U Hasibuan; Imam B Putra; Nelva K Jusuf
Journal:  Open Access Maced J Med Sci       Date:  2017-06-11

3.  Neutrophil to lymphocyte ratio in patients with vitiligo.

Authors:  Berna Solak; Bahar Sevimli Dikicier; Nur Cihan Cosansu; Teoman Erdem
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.